Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2007-07-10
2007-07-10
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C514S357000, C514S438000, C546S337000, C549S077000, C564S194000
Reexamination Certificate
active
11204266
ABSTRACT:
The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 2406366 (1946-08-01), Graef
patent: 2423579 (1947-07-01), Buren
patent: 5604229 (1997-02-01), Fujita et al.
patent: 5719176 (1998-02-01), Fujita et al.
patent: 5948820 (1999-09-01), Fujita et al.
patent: 5952316 (1999-09-01), Fujita et al.
patent: 6004565 (1999-12-01), Chiba et al.
patent: 6187821 (2001-02-01), Fujita et al.
patent: 6214873 (2001-04-01), Adachi et al.
patent: 6372800 (2002-04-01), Fujita et al.
patent: 6437165 (2002-08-01), Mandala et al.
patent: 6969692 (2005-11-01), Brady et al.
patent: 7064217 (2006-06-01), Macdonald et al.
patent: 2002/0042358 (2002-04-01), Spiegel
patent: 2002/0072502 (2002-06-01), Ho
patent: 2002/0137916 (2002-09-01), Loughran et al.
patent: 2003/0027800 (2003-02-01), Miller et al.
patent: 2003/0096022 (2003-05-01), Sabbadini
patent: 2004/0034075 (2004-02-01), Smith et al.
patent: 2004/0048857 (2004-03-01), Pan et al.
patent: 2004/0122236 (2004-06-01), Lynch et al.
patent: 2004/0254222 (2004-12-01), Kohno et al.
patent: 2005/0222422 (2005-10-01), Lynch et al.
patent: 2006/0166940 (2006-07-01), Buehimayer et al.
patent: 1602660 (2005-12-01), None
patent: WO 9848794 (1998-11-01), None
patent: WO-02/18395 (2002-03-01), None
patent: WO-02/29001 (2002-04-01), None
patent: WO-02/064616 (2002-08-01), None
patent: WO-02/076995 (2002-10-01), None
patent: WO-03/029205 (2003-04-01), None
patent: WO-03/061567 (2003-07-01), None
patent: WO-03/062252 (2003-07-01), None
patent: WO-03/097028 (2003-11-01), None
patent: WO-2004/010949 (2004-02-01), None
patent: WO-2004/010987 (2004-02-01), None
patent: WO-2004/024673 (2004-03-01), None
patent: WO-2004/026817 (2004-04-01), None
patent: WO-2004/058149 (2004-07-01), None
patent: WO-2004/061107 (2004-07-01), None
patent: WO-2004/096752 (2004-11-01), None
patent: WO-2004/096757 (2004-11-01), None
patent: WO-2004/103279 (2004-12-01), None
patent: WO-2004/110979 (2004-12-01), None
patent: WO-2005/000833 (2005-01-01), None
patent: WO-2005/041899 (2005-05-01), None
patent: WO-2005/054215 (2005-06-01), None
patent: WO-2005/085179 (2005-09-01), None
patent: WO-2005/115150 (2005-12-01), None
patent: WO-2005/118523 (2005-12-01), None
patent: WO-2006/009092 (2006-01-01), None
patent: WO-2006/010379 (2006-02-01), None
patent: WO-2006/010544 (2006-02-01), None
patent: WO-2006/047195 (2006-05-01), None
patent: WO-2006/052723 (2006-05-01), None
patent: WO-2006/058316 (2006-06-01), None
patent: WO-2006/063033 (2006-06-01), None
patent: WO-2006/064757 (2006-06-01), None
Albert, Rainer et al, “Novel Immunomodulator FTY720 Is Phosphorylated in Rats and Humans to Form a Single Stereoisomer. Identification, Chemical Proof, and Biological Characterization of the Biologically Active Species and Its Enantiomer,”J. Med. Chem., vol. 48:5373-5377 (2005).
An, Songzhu, “Molecular Identification and Characterization of G Protein-Coupled Receptors for Lysophosphatidic Acid and Sphingosine 1-Phosphate,”Annals New York Academy of Sciences, vol. 95:25-33 (2000).
Bai, Yalai et al, “L-Selectin-Dependent Lymphoid Occupancy Is Required to Induce Alloantigen-Specific Tolerance,”The Journal of Immunology, vol. 168:1579-1589 (2002).
Bandhuvula, Padmavathi et al, “The Immune Modulator FTY720 Inhibits Sphingosine-1-phosphate Lyase Activity,”The Journal of Biological Chemistry, vol. 280(40):33697-33700 (2005).
Baudhuin, Linnea M. et al, “Akt Activation Induced by Lysophosphatidic Acid and Sphingosine-1-phosphate Requires Both Mitogen-Activated Protein Kinase Kinase and p38 Mitogen-Activated Protein Kinase and Is Cell-Line Specific,”Molecular Pharmacology, vol. 62(3):660-671 (2002).
Billich, Andreas et al, “Phosphorylation of the Immunomodulatory Drug FTY720 by Sphingosine Kinases,”The Journal of Biological Chemistry, vol. 278(48):47408-47415 (2003).
Böhler, T. et al, “FTY 720Amediates reduction of lymphocyte counts in human renal allograft recipients by an apoptosis-independent mechanism,”Transpl. Int., vol. 13(Suppl. 1):S311-S313 (2000).
Brinkmann, Volker et al, “Pulmonary and vascular pharmacology of sphingosine 1-phosphate,”Current Opinion in Pharmacology, vol. 6:244-250 (2006).
Brinkmann, Volker et al, “The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors,”The Journal of Biological Chemistry, vol. 277(24):21453-21457 (2002).
Brown, Michael S. et al, “A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood,”Proc. Natl. Acad. Sci. USA, vol. 96:11041-11048 (1999).
Budde, Klemens et al, “First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients,”J. Am. Soc. Nephrol., vol. 13:1073-1083 (2002).
Budde, Klemens et al, “Pharmacodynamics of Single Doses of the Novel Immunosuppressant FTY720 in Stable Renal Transplant Patients,”American Transplantation, vol. 3:846-854 (2003).
Chiba, K. et al, “Immunosuppressive Activity of FTY720, Sphingosine 1-Phosphate Receptor Agonist: I. Prevention of Allograft Rejection in Rats and Dogs by FTY720 and FTY720-Phosphate,”Transplantation Proceedings, vol. 37:102-106 (2005).
Chiba, Kenji et al, “FTY720, a Novel Immunosuppressant Induces Sequestration of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing in Rats. I. FTY720 Selectively Decreases the Number of Circulating Mature Lymphocytes by Acceleration of Lymphocyte Homing,”The Journal of Immunology, vol. 160:5037-5044 (1998).
Chua, Chee-Wai et al, “FTY720, a fungus metabolite, inhibits in vivo growth by androgen-independent prostate cancer,”Int. J. Cancer, vol. 117:1039-1048 (2005).
Chueh, Shih-Chieh J. et al, “Update on FTY720: review of mechanisms and clinical results,”Current Opinion in Organ Transplantation, vol. 8:288-298 (2003).
Chun, Jerold et al, “International Union of Pharmacology. XXXIV. Lysophospholipid Receptor Nomenclature,”Pharmacological Reviews, vol. 54(2):265-269 (2002).
Chun, Jerold et al, “Lysophospholipid Receptors as Potential Drug Targets in Tissue Transplantation and Autoimmune Diseases,”Current Pharmaceutical Design, vol. 12:161-171 (2006).
Clemens, Jeremy J. et al, “Synthesis ofPara-Alkyl Aryl Amide Analogues of Sphingosine-1-phosphate: Discovery of Potent S1P Receptor Agonists,”Bioorganic&Medicinal Chemistry Letters, vol. 13:3401-3404 (2003).
De Jonghe, Steven et al, “Structure-Activity Relationship of Short-Chain Sphingoid Bases as Inhibitors of Sphingosine Kinase,”Bioorganic&Medicinal Chemistry Letters, vol. 9:3175-3180 (1999).
Drugs of the Future, “FTY-720,” vol. 27(5):501-506 (2002).
Dumont, Francis J., “Fingolimod Mitsubishi Pharma/Novartis,”IDrugs, vol. 8(3):236-253 (2005).
Ettmayer, Peter et al, “NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies,”Bioorganic&Medicinal Chemistry Letters, vol. 16:84-87 (2006).
Fang, Xianjun et al, “Lysophospholipid Growth Factors in the Initiation, Progression, Metastases, and Management of Ovarian Cancer,”Annals of New York Academy of Sciences, vol. 905:188-208 (2000).
Forrest, M. et al, “Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes,”The Journal of Pharmacology and Experimental Therapeutics, vol. 309(2):758-768 (2004).
Gijsbers, Sofie et al, “1-O-Hexadecyl-2-desoxy-2-amino-sn-glycerol, a substrate for human sphingosine kinase,”Biochimica et Biophysica Acta, vol. 1580:1-8 (2002).
Gon, Yasuhiro et al, “S1P3 Receptor-induced reorganization of epithelial tight junctions compromises lung barrier
Evindar Ghotas
Kavarana Malcolm J.
Morgan Barry
Saha Ashis K.
Satz Alexander L.
DeConti Giulio A.
Kosack Joseph R.
Laccotripe Zacharakis Maria
Lahive & Cockfield LLP
Praecis Pharmaceuticals Inc.
LandOfFree
Methods and compositions for modulating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for modulating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3724261